Genocea Biosciences Inc. (NASDAQ:GNCA)’s share price shot up 4.1% during trading on Tuesday . The stock traded as high as $5.37 and last traded at $5.35, with a volume of 82,497 shares traded. The stock had previously closed at $5.14.

Several research firms have commented on GNCA. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Buy” and an average target price of $17.95.

The stock’s 50 day moving average price is $4.67 and its 200-day moving average price is $4.53. The stock’s market capitalization is $151.87 million.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, equities analysts predict that Genocea Biosciences Inc. will post ($1.63) EPS for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.